Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 5, 2008, Pages 597-607

  Hubensack, Martina ^a   Müller, Christine ^a   Höcherl, Peter ^a   Fellner, Stephan ^a   Spruss, Thilo ^a   Bernhardt, Günther ^a   Buschauer, Armin ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

ABCB1; Blood brain barrier; Elacridar; P glycoprotein 170; Paclitaxel; Tariquidar; Valspodar

Indexed keywords

DOCETAXEL; ELACRIDAR; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TARIQUIDAR; VALSPODAR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG PENETRATION; FLOW CYTOMETRY; KIDNEY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TRANSPORT KINETICS;

ACRIDINES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; FLOW CYTOMETRY; MICE; MICE, NUDE; PACLITAXEL; QUINOLINES; TETRAHYDROISOQUINOLINES;

EID: 41049096756     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0323-9     Document Type: Article

References (43)

1. Bauer B, Hartz AMS, Fricker G, Miller DS (2005) Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp Biol Med 230(2):118-127
2. Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104(1):29-45
3. Bernhardt G, Reile H, Birnböck H, Spruss T, Schönenberger H (1992) Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J Cancer Res Clin Oncol 118(1):35-41
4. Boniface GR, Ferry DR, Atsmon J, Inbar M, van Tellingen O, Abraham J, Bates SE, Fajo AT, Thomas H, Mould G, Steiner J, Mellows G (2002) XR 9576 (tariquidar), a potent and specific p-glycoprotein inhibitor, has minimal effects on the pharmacokinetics of paclitaxel, doxorubicin, and vinorelbine and can be administered with full-dose chemotherapy in patients with cancer. Proc Am Soc Clin Oncol 21 (abstract 2173)
5. Brandes AA, Pasetto LM, Monfardini S (2000) New drugs in recurrent high grade gliomas. Anticancer Res 20(3B):1913-1920
6. Breedveld P, Beijnen JH, Schellens JHM (2006) Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27(1):17-24
7. Dodic N, Dumaitre B, Daugan A, Pianetti P (1995) Synthesis and activity against multidrug resistance in Chinese hamster ovary cells of new acridone-4-carboxamides. J Med Chem 38(13):2418-2426
8. Edwards JE, Brouwer KR, McNamara PJ (2002) GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats. Antimicrob Agents Chemother 46(7):2284-2286
9. Egger M, Li X, Müller C, Bernhardt G, Buschauer A, König B (2007) Tariquidar analogues: synthesis by Cu(I)-catalysed N/O-aryl coupling and inhibitory activity against the ABCB1 transporter. Eur J Org Chem (16):2643-2649
10. Fellner S (2001) Pharmakokinetische und pharmakodynamische Untersuchungen zur Koapplikation von MDR-Modulatoren (SDZ PSC 833) und Hyaluronidase bei der Chemotherapie maligner Gliome. Doctoral thesis. University of Regensburg, Regensburg, Germany
11. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruss T, Bernhardt G, Gräff C, Färber L, Gschaidmeier H, Buschauer A, Fricker G (2002) Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110(9):1309-1318
12. Fischer V, Rodriguez-Gascon A, Heitz F, Tynes R, Hauck C, Cohen D, Vickers AEM (1998) The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 26(8):802-811
13. Fricker G, Miller DS (2004) Modulation of drug transporters at the blood-brain barrier. Pharmacology 70(4):169-176
14. Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25(8):423-429
15. Glantz MJ, Chamberlain MC, Chang SM, Prados MD, Cole BF (1999) The role of paclitaxel in the treatment of primary and metastatic brain tumors. Semin Radiat Oncol 9(2 Suppl 1):27-33
16. Homolya L, Hollo Z, Germann U, Pastan I, Gottesman M, Sarkadi B (1993) Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 268(29):21493-21496
17. Hubensack M (2005) Approaches to overcome the blood brain barrier in the chemotherapy of primary and secondary brain tumors: modulation of P-glycoprotein 170 and targeting of the transferrin receptor. Doctoral thesis. University of Regensburg, Regensburg, Germany. http://www.opus-bayern.de/uni-regensburg/ volltexte/2005/471/
18. Huisman MT, Smit JW, Wiltshire HR, Beijnen JH, Schinkel AH (2003) Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir. J Pharmacol Exp Ther 304(2):596-602
19. Hyafil F, Vergely C, Du Vignaud P., Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53(19):4595-4602
20. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, van Tellingen O (2003) Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 9(7):2849-2855
21. Kemper EMVM, Boogerd W, Beijnen JH, Van Tellingen O (2004) Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer 40(8):1269-1274
22. Kohno K, Kikuchi J, Sato S, Takano H, Saburi Y, Asoh K, Kuwano M (1988) Vincristine-resistant human cancer KB cell line and increased expression of multidrug-resistance gene. Jpn J Cancer Res 79(11):1238-1246
23. Kruijtzer CMF, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JHM (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20(13):2943-2950
24. Kurnik D, Wood AJJ, Wilkinson GR (2006) The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther 80(3):228-234
25. Labrie P, Maddaford SP, Lacroix J, Catalano C, Lee DK, Rakhit S, Gaudreault RC (2007) In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2). Bioorg Med Chem 15(11):3854-3868
26. Letrent SPPGM, Brouwer KR, Brouwer KL (1998) Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm Res 15(4):599-605
27. Löscher W, Potschka H (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6(8):591-602
28. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P (2001) In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61(2):749-758
29. Müller C, Gross D, Sarli V, Gartner M, Giannis A, Bernhardt G, Buschauer A (2007) Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells. Cancer Chemother Pharmacol 59(2):157-164
30. Roe M, Folkes A, Ashworth P, Brumwell J, Chima L, Hunjan S, Pretswell I, Dangerfield W, Ryder H, Charlton P (1999) Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett 9(4):595-600
31. Scherrmann JM (2002) Drug delivery to brain via the blood-brain barrier. Vasc Pharmacol 38(6):349-354
32. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J (2003) Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem 46(9):1716-1725
33. Sharp MJ, Mader CJ, Strachan C (1998) Synthesis of acridine derivative as multidrug-resistant inhibitor. Patent WO 98-EP2991 19980522
34. Sparreboom A, van Tellingen O, Nooijwn WJ, Beijnen JH (1995) Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl 664(2):383-391
35. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94(5):2031-2035
36. Sparreboom A, Planting AST, Jewell RC, Van der Burg MEL, Van der Gaast A, De Bruijn P, Loos WJ, Nooter K, Chandler LH, Paul EM, Wissel PS, Verweij J (1999) Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 10(8):719-728
37. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P (2000) Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 6(11):4186-4191
38. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219-234
39. Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10(2):159-165
40. Tian Q, Zhang J, Chan E, Duan W, Zhou S (2005) Multidrug resistance proteins (MRPs) and implication in drug development. Drug Dev Res 64(1):1-18
41. van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH (1997) Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76(9):1181-1183
42. Wandel C, Kim RB, Kajiji S, Guengerich FP, Wilkinson GR, Wood AJ (1999) P-Glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59(16):3944-3948
43. Ward KW, Azzarano LM (2004) Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5- methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl] phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey. J Pharmacol Exp Ther 310(2):703-709